GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
Jim Cramer Says ‘Buy and Put Away’ GSK (GSK) for Its 4% Yield
GSK plc (NYSE:GSK) is engaged in research, development, and production of vaccines, as well as specialized and general medicines aimed at preventing and treating various diseases. In early March, ...
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth
While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...